Heron Therapeuti (HRTX)vsVertex Pharmaceuticals Inc (VRTX)
HRTX
Heron Therapeuti
$0.28
-8.44%
HEALTHCARE · Cap: $56.69M
VRTX
Vertex Pharmaceuticals Inc
$537.79
-0.15%
HEALTHCARE · Cap: $137.57B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 8467% more annual revenue ($12.95B vs $151.18M). VRTX leads profitability with a 30.7% profit margin vs -22.5%. VRTX earns a higher WallStSmart Score of 58/100 (C).
HRTX
Avoid29
out of 100
Grade: F
VRTX
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HRTX.
Margin of Safety
+44.9%
Fair Value
$977.14
Current Price
$537.79
$439.35 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 37.8%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Areas to Watch
Trading at 9.5x book value
1.3% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 39.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : HRTX
HRTX has a balanced fundamental profile.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 30.7% and operating margin at 37.8%. Revenue growth of 11.8% demonstrates continued momentum.
Bear Case : HRTX
The primary concerns for HRTX are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 26.80 is elevated, increasing financial risk.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
HRTX profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.
HRTX carries more volatility with a beta of 1.65 — expect wider price swings.
VRTX is growing revenue faster at 11.8% — sustainability is the question.
VRTX generates stronger free cash flow (546M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (58/100 vs 29/100), backed by strong 30.7% margins and 11.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Heron Therapeuti
HEALTHCARE · BIOTECHNOLOGY · USA
Heron Therapeutics, Inc., a biotechnology company, is dedicated to developing treatments to address unmet medical needs. The company is headquartered in San Diego, California.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?